These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15228865)

  • 41. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma.
    Froschermaier SE; Pilarsky CP; Wirth MP
    Urology; 1996 Apr; 47(4):525-8. PubMed ID: 8638361
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
    Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
    J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate.
    Amayo A; Obara W
    East Afr Med J; 2004 Jan; 81(1):22-6. PubMed ID: 15080511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic value of prostate-specific antigen-related parameters in discriminating prostate cancer.
    Matsuyama H; Baba Y; Yamakawa G; Yamamoto N; Naito K
    Int J Urol; 2000 Nov; 7(11):409-14. PubMed ID: 11144651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
    Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
    J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
    Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
    Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical evaluation of percent free prostate-specific antigen using the AxSYM system in the best analytical scenario.
    Gion M; Mione R; Barioli P; Barichello M; Zattoni F; Prayer-Galetti T; Plebani M; Aimo G; Terrone C; Manferrari F; Madeddu G; Caberlotto L; Fandella A; Pianon C; Vianello L; Amoroso B
    Eur Urol; 2000 Apr; 37(4):460-9. PubMed ID: 10765078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Study of free to total prostate specific antigen ratio in the detection of patients with prostate cancer].
    Ohuchi H; Mikata K; Miyoshi Y; Ohta J; Osada Y; Uemura H; Yao M; Takeda M; Noguchi S; Kubota Y; Hosaka M; Jinza S; Asakura T; Ebato T
    Nihon Hinyokika Gakkai Zasshi; 2000 Dec; 91(12):695-9. PubMed ID: 11201129
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
    Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
    Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer.
    Pearson JD; Luderer AA; Metter EJ; Partin AW; Chan DW; Fozard JL; Carter HB
    Urology; 1996 Dec; 48(6A Suppl):4-9. PubMed ID: 8973693
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate-specific antigen levels and density in the internal and external glands of the prostate in benign prostatic hyperplasia patients with normal or gray-zone PSA levels.
    Zuo W; Hiraoka Y
    Urol Int; 2003; 71(2):154-9. PubMed ID: 12890952
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Free-to-total prostate-specific antigen serum concentrations in patients with prostate cancer and benign prostatic hyperplasia.
    Wolff JM; Borchers H; Effert PJ; Habib FK; Jakse G
    Br J Urol; 1996 Sep; 78(3):409-13. PubMed ID: 8881952
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Usefulness of the percentage of free prostatic specific antigen in the differential diagnosis between benign prostatic hyperplasia and prostate cancer].
    Gaspar MJ; Arribas I; Hontoria JM; Bokobo P; Coca C; Angulo JC
    Med Clin (Barc); 2000 Sep; 115(9):332-6. PubMed ID: 11093893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer.
    Veltri RW; Miller MC; Zhao G; Ng A; Marley GM; Wright GL; Vessella RL; Ralph D
    Urology; 1999 Jan; 53(1):139-47. PubMed ID: 9886603
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical efficacy of prostate-specific antigen testing in patients with prostate disease.
    Yu HJ; Chie WC; Hsieh CH; Tsai CC; Lai MK
    J Formos Med Assoc; 1996 Oct; 95(10):782-8. PubMed ID: 8961676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions.
    Gion M; Mione R; Barioli P; Barichello M; Zattoni F; Prayer-Galetti T; Plebani M; Aimo G; Terrone C; Manferrari F; Madeddu G; Caberlotto L; Fandella A; Pianon C; Vianello L
    Clin Chem; 1998 Dec; 44(12):2462-70. PubMed ID: 9836713
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urinary prostate specific antigen: is the clinical use likely?
    Pejcic T; Hadzi-Djokic J; Acimovic M; Topuzovic C; Milkovic B; Janjic A
    Acta Chir Iugosl; 2005; 52(4):69-74. PubMed ID: 16673599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.